Background: New therapies for asthma which can address three main interrelated features of the disease, airway inflammation, airway remodeling and airway hyperreactivity, are urgently required. Resveratrol, a well known red wine polyphenol has received much attention due to its potential anti-aging properties. This compound is an agonist of silent information regulator two histone deacetylases and has many effects that are relevant to key aspects of the pathophysiology of asthma including inflammation, cell proliferation and fibrosis. Therefore, resveratrol may offer a novel asthma therapy that simultaneously inhibits airway inflammation, and airway remodeling which are the main contributors to airway hyperreactivity and irreversible lung function loss. Methods: We evaluated the effects of systemic resveratrol treatment in a murine model of chronic allergic airways disease which displays most of the clinicopathological features of severe human asthma. Wild-type Balb/c mice with allergic airways disease were treated with 12.5 mg/kg resveratrol or vehicle control. Airway inflammation was assessed by bronchoalveolar lavage fluid cell counts and histological examination of lung tissue sections. Further, remodeling was assessed by morphometric analysis and lung function was assessed by invasive plethysmography measurement of airway resistance and dynamic compliance. Results: Mice treated with resveratrol exhibited reduced tissue inflammation as compared to vehicle treated mice (p B0.05). Additionally, resveratrol treatment resulted in reduced subepithelial collagen deposition as compared to vehicle treated mice (pB0.05) and attenuated airway hyperreactivity (p B0.05). Conclusions: These novel findings demonstrate that treatment with resveratrol can reduce structural airway remodeling changes and hyperreactivity. This has important implications for the development of new therapeutic approaches to asthma.
S
evere asthma can be a difficult disease to treat as it consists of three interrelated pathologies: airway inflammation, airway remodeling, and airway hyperreactivity (AHR) (1, 2) . The mainstay of asthma therapeutics is inhaled corticosteroids. These drugs are very effective at treating airway inflammation; however, they have a number of important limitations. Firstly, steroid resistance, where a subpopulation of patients with asthma shows poor response to the drugs, is a concern. Secondly corticosteroids cannot be used at the highest and optimal concentrations in young children. preventing and reversing airway remodeling changes (3) . These structural changes in the airway wall include goblet cell metaplasia and mucous hypersecretion, subepithelial fibrosis, smooth muscle thickening, and angiogenesis (4, 5) . Airway remodeling occurs early in disease pathogenesis, can interact with and promote chronic inflammation, and contributes to AHR resulting in progressive irreversible loss of lung function (2) . Therefore, there is a need for identification of novel treatments that can prevent and/or reverse airway remodeling changes and inhibit AHR in addition to abrogating airway inflammation.
Resveratrol (3, 4 ?,5-trihydroxystilbene), a polyphenolic agonist of silent information regulator two histone deacetylases (sirtuins, class III HDAC) is a compound found in the skin of red fruits (e.g. red grapes, a constituent of red wine) and medicinal plants (6Á8). The anticancer, anti-inflammatory, and anti-oxidant effects of this compound have been reported in numerous mouse and rat models (9) . The anti-inflammatory effects of resveratrol have been associated with the inhibition of cyclooxygenase (COX)-2 transcription and inhibition of COX-1 activity via a peroxidase-mediated mechanism (10). In the experimental rat carrageenan-induced paw edema model, resveratrol inhibited both acute and chronic inflammation (11) . It has also shown to protect cartilage against the progression of inflammatory arthritis in a rabbit arthritis model (12) .
The effects of resveratrol have also been attributed, at least in part, to the inhibition of nuclear factor kappa B (NF-kB) via the inhibition of IkB kinase (13) . The NFkB is an important transcription factor involved in the expression of numerous inflammation-associated proteins such as GM-CSF, IL-8, COX-2, and inducible nitric oxide synthase (iNOS). Activation of airway inflammation releases reactive oxygen species (ROS) leading to oxidative stress. The NF-kB activation is necessary for the expression of various inflammatory proteins such as GM-CSF and IL-8 (released by alveolar macrophages/ polymorphonuclear cells from patients with COPD (14), COX-2, and iNOS (15, 16) . Hence NF-kB inhibition, possibly via inhibition of IkB kinase (17) , may reduce the expression of inflammatory genes, a mechanism by which glucocorticosteroids may also function (18) . Resveratrol has also been known to mitigate the release of inflammatory mediators whilst having a limited effect on VEGF (protects from development of emphysema) in COPD (19) . Furthermore, the anti-inflammatory effects of resveratrol may be due to inhibition of activator protein-1 (AP-1), which is also a potent regulator of oxidative stress related genes (20) .
Importantly, airway inflammation has been shown to be suppressed by resveratrol in an acute mouse model of allergic airways disease, producing similar effects to glucocorticoids (dexamethasone) (21) . Overall, resveratrol has potent anti-inflammatory and anti-oxidative functions and, therefore, may be useful in the treatment of airway diseases such as asthma. We aimed to investigate the effects of resveratrol in a murine model of chronic allergic airways disease that displays most of the features of human asthma on airway inflammation, airway remodeling structural changes, and AHR.
Materials and methods

Animals
Six-week-old female Balb/c mice were housed under specific pathogen-free conditions and maintained on a fixed 12 hour light, 12 hour dark lighting schedule. Balb/c mice demonstrate strong Th2 responses in ovalbumin (OVA)-induced allergic airways disease models (22Á24). All experimental procedures were approved by the Murdoch Children's Research Institute Animal Ethics Committee and followed the Australian Guidelines for the Care and Use of Laboratory Animals for Scientific Purposes.
Mouse model of chronic allergic airways disease An established model of OVA-induced chronic allergic airways disease was used as previously described (25, 26) . This model includes many of the pathological features of human asthma including increased allergic responses indicated by increased immunoglobulin E against OVA (OVA-specific IgE), AHR, and remodeling changes such as epithelial remodeling, goblet cell metaplasia, and subepithelial collagen deposition (fibrosis). However, it does not display smooth muscle hyperplasia (25, 26) . Briefly, mice were sensitized with 10 mg of grade V OVA (Sigma Chemical, St. Louis, MO) and 1 mg of aluminum potassium sulfate adjuvant (alum) in 500 ml saline i.p on day 0 and 14 and then challenged with nebulized 2.5% (w/v) OVA in saline 3 days per week for 6 weeks to establish AAD.
Ovalbumin-exposed mice were treated with resveratrol (OVA-RV, n015) or vehicle control (OVA-VEH, n015) intraperitoneally following each OVA nebulization (3 days per week for 6 weeks). A third group of mice, sensitized with saline/alum on days 0 and 14 and nebulized with saline 3 days per week for 6 weeks (n015), served as additional controls. Resveratrol (Sigma Chemical) was used at a dose of 12.5 mg/kg in 20% ethanol/0.9% saline, which is known to be biologically active and has been used widely in experimental murine models of disease with minimal toxicity (27, 28) .
Methacholine-induced AHR
Forty-eight hours after the last OVA nebulization/ treatment with resveratrol or vehicle, AHR was measured using a mouse invasive plethysmograph (Buxco Electronics, Troy, NY) as described previously (25) . Mice were anesthetized by i.p. injection of ketamine (200 mg/kg) and xylazine (10 mg/kg) and tracheostomized. After baseline airway resistance had been recorded, increasing methacholine doses (0.25, 0.5, 1, 2, 4, and 8 mg/ml) were delivered by nebulizer (Buxco Electronics) and airway resistance change from baseline level were measured (Finepointe, Buxco Electronics) for 3 min after each dose.
Quantitation of serum OVA-specific IgE levels Serum was obtained by lethal cardiac puncture of anesthetized mice after AHR measurement and stored frozen at (708C for measurement of OVA-specific IgE by ELISA (25, 29, 30) . OVA-specific IgE levels were expressed as mean optical density (OD) at 490 nm.
Bronchoalveolar lavage (BAL)
Following measurement of airway reactivity, BAL was performed by three washes of 0.5 ml saline containing 5% (v/v) fetal calf serum and total and differential cell counts of inflammatory cells determined (25, 31) . Total viable cell counts were determined using a hemocytometer with trypan blue exclusion. Differential counts of eosinophils, neutrophils, lymphocytes, and monocytes/macrophages were determined on cytospin smears of BAL samples (4 )10 5 cells) from individual mice stained with DiffQuick (Life Technologies, Auckland, New Zealand) and identified by standard morphological criteria after counting 300 cells.
Tissue collection
Lung tissues were immediately dissected and weighed (total lung weight) and then separated into individual lobes for histological analysis (25, 29, 32) .
Lung histopathology
The right lung was fixed in formalin, routinely processed, and embedded in paraffin (25, 29, 32) . Three mm lung tissue sections were stained with Masson trichrome for assessment of epithelial and subepithelial collagen thickness and Alcian blue-periodic acid Schiff (AB-PAS) for assessment of goblet cell numbers (25, 29, 32) .
Airway tissue inflammation cell score
The degree of airway inflammatory cell infiltration was scored by two independent blinded investigators. The degree of airway inflammatory cell infiltration around the bronchi was scored as 0 for no inflammatory cell infiltration, 1 for 3 layers of inflammatory cells, 2 for 6 layers, 3 for 10 layers and congestion, or 4 for more than 10 layers of inflammatory cells and severe congestion. For each mouse, five airways were observed and the average scores were taken.
Morphometric analysis of structural changes
Morphometric analysis of lung tissue sections was performed as described previously (25, 29, 33) . Images of lung tissue sections were captured using a Digital camera (Q Imaging, Burnaby, BC, Canada). A minimum of five bronchi measuring 150Á350 mm luminal diameter were analyzed per mouse using Image Pro-Discovery software (Media Cybernetics, Silver Spring, MD), which was calibrated with a reference micrometer slide. The thickness of the bronchial epithelial layer was measured by tracing around the basement membrane and the luminal surface of epithelial cells using a digitizer (Aiptek, Irvine, CA) and calculating the mean distance between the lines by Image Pro-Discovery software (Media Cybernetics). Subepithelial collagen thickness was also measured by tracing around the outer extent of the total collagen layer in the submucosal region, around the basement membrane, and the mean distance between these lines calculated. For goblet cell determination, the basement membrane length was measured by tracing in Image Pro-Discovery software (Media Cybernetics) and goblet cells were counted in AB-PAS stained sections and expressed as number of cells per 100 mm of basement membrane.
Immunohistochemistry for TGF-b1
Sections of lung tissue were stained by immunohistochemistry to detect TGF-b1 protein expression. The TGFb1 was identified using rabbit polyclonal antibodies, sc-146, specific for TGF-b1 (Santa Cruz Biotechnology, Santa Cruz, CA). Bound primary antibody was detected using anti-rabbit EnVision (Dako, Glostrup, Denmark). The chromagen 3,3-diaminobenzidine was used and sections were counterstained with hematoxylin. 
Statistical analysis
Results were expressed as mean9SEM with 95% confidence interval and analyzed using the MannWhitney test.
Results
Validation of the chronic allergic airways disease model It was first necessary to validate that OVA sensitization/ challenge had been successfully established in the OVA mice treated with vehicle (OVA-VEH). Allergen-specific immunoglobulin E (OVA-specific IgE), AHR, BAL inflammatory cells, goblet cell hyperplasia, and remodeling changes such as epithelial remodeling and peribronchial fibrosis were assessed. The OVA sensitization was verified by measurement of OVA-specific IgE in serum samples at the end of the 8 week OVA sensitization/challenge protocol. As expected, OVA-VEH mice demonstrated increased levels of OVA-specific serum IgE compared to saline control mice (pB0.001; Fig. 1 ). Total and differential BAL cell counts were significantly increased in OVA-VEH mice as compared with the saline sensitized/ challenged control mice (all pB0.001; Fig. 2 ). Airway inflammation was significantly increased in OVA sensitized/challenged mice treated with vehicle (OVA-VEH) as compared with the saline control mice (pB 0.001; Figs. 3 and 4) . The AHR was significantly increased in the OVA-VEH group when compared to the saline control mice (pB0.001; Fig. 5 ). The OVA-VEH mice also developed airway remodeling changes with increased goblet cell numbers (pB0.001; Fig. 6 ), epithelial thickness (p B0.001; Fig. 7) , and subepithelial collagen deposition (p B0.001; Fig. 8 ) as compared to the saline control mice. These results confirmed that the allergic airways disease model was successfully established with development of airway inflammation, airway remodeling, and AHR as previously reported (25, 26, 29, 34) .
Effect of resveratrol on airway inflammation in chronic allergic airways disease
The OVA-specific IgE levels in OVA sensitized/challenged mice treated with resveratrol (OVA-RV) were similar to levels in OVA sensitized/challenged mice treated with vehicle (OVA-VEH), and levels in both the OVA-RV and OVA-VEH groups were significantly higher than levels in saline sensitized/challenged control mice confirming successful OVA sensitization in both groups (pB0.001; Fig. 1 ).
Total and differential BAL cell counts were not significantly different when compared to the vehicle treated mice (OVA-VEH) (Figs. 2 and 9) . These results indicate that systemic (intraperitoneal) administration of resveratrol does not significantly inhibit numbers of BAL inflammatory cells following sensitization/challenge with OVA at the completion of the chronic OVA challenge model.
Treatment with resveratrol suppresses airway remodeling changes in subepithelial collagen deposition but not epithelial thickening and goblet cell metaplasia in chronic allergic airways disease Goblet cell numbers were determined in AB-PAS stained lung tissue sections, while airway epithelial thickness and subepithelial ECM thickness were determined in Masson trichrome stained lung tissue sections. Subepithelial extracellular matrix thickness was significantly lower in resveratrol-treated mice as compared to vehicle treated mice (p B0.05), but remained higher than that observed in the saline sensitized/challenged mice (p B0.05; Figs. 8 and 10) .
Percentages of goblet cells in resveratrol treated mice were not significantly different than in vehicle treated Fig. 9 . BALF differential cell counts. Following Diff-quick staining, numbers of differential cells were counted under the light microscope. The value expressed as total number in 1 ml sample. Eosinophils, neutrophils, lymphocytes, and monocytes was significantly increased in OVA-VEH and OVA-RV mice as compared to saline mice (**p B0.01; ***p B0.001), n 010 per group. mice (pB0.05; Figs. 6 and 11), but remained significantly higher than in the saline sensitized/challenged mice (pB 0.001). The mean epithelial thickness was not significantly different in OVA-RV and OVA-VEH mice, and airway epithelial thickness in both groups was significantly increased as compared to saline sensitized/challenged mice (p B0.001; Figs. 7 and 10 ). These results suggest that resveratrol can regulate some aspects of airway remodeling (fibrosis) but not epithelial remodeling.
Treatment with resveratrol attenuates AHR in chronic allergic airways disease Anesthetized tracheotomized mice were challenged with nebulized methacholine and the change in resistance from baseline was measured by invasive plethysmography. Methacholine-induced AHR was reduced in the OVA-RV group as compared to the OVA-VEH group, with statistical significance reached at doses of 4 mg/ml and 8 mg/ml of methacholine (pB0.05; Fig. 5 ). These results show that resveratrol treatment can suppress AHR in the chronic allergic airways disease model.
Immunohistochemical analysis of TGFb1 expression
The TGFb1 was investigated by immunohistochemistry in formalin-fixed, paraffin-embedded lung tissue sections (Fig. 12) . Little constitutive staining for TGFb1 was observed in the saline-sensitized and -challenged 
Discussion
We investigated the potential of resveratrol treatment for asthma using a chronic murine model of allergic airways disease. We assessed the effect of the drug in preventing airway remodeling and suppressing AHR. Our findings indicate that resveratrol suppressed AHR and inhibited the development of subepithelial bronchial fibrosis. This effect on fibrosis involved reduced TGFb protein expression in the airways of mice treated with resveratrol. In our study we did not see significant reduction in BAL fluid inflammatory cell numbers although we did we see modest reduction in lung tissue inflammation infiltrate in the chronic allergic airways disease mice treated with resveratrol. This likely reflects the treatment regimen used and the chronic ovalbumin model that exhibits only moderate inflammation and eosinophilia compared to the acute and subacute models of allergic airways disease (29) . One of the major features of the chronic allergic airways disease model is the relatively high AHR to methacholine. In the current study we found that resveratrol resulted in lower AHR at high concentrations of methacholine. The AHR is the most important clinical endpoint in asthma; increased AHR is not only symptomatic of asthma but is a correlate of disease severity (GINA guidelines) and can be used for diagnosis and monitoring the disease. Whilst we only demonstrate modest evidence of action on airway inflammation, resveratrol had a powerful anti-remodeling activity, particularly in airway subepithelial fibrosis. Airway fibrosis is an important pathological process in many airway diseases including chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and scleroderma. Fibrotic remodeling of the basement membrane, the formation of the lamina reticularis, is pathognomonic of asthma and correlates with severity in endobronchial biopsies from asthma sufferers (35) . Fibrosis in the lamina reticularis, lamina propria, and serosa contributes to the overall thickness of the airway wall that impacts AHR (36, 37) . Furthermore, extracellular matrix is deposited between airway smooth muscle cells in asthma (38) . Extracellular matrix not only contributes to increased muscle mass for AHR but matrix components such as collagen I have been shown in vitro to promote airway smooth muscle cell proliferation (39) .
Airway fibrosis in asthma is due to extracellular matrix deposition by fibroblasts and is accompanied by differentiation of myofibroblasts, activated fibroblasts with contractile properties, and a smooth muscle actin expression. These processes are regulated by TGFb, a potent profibrotic cytokine. The TGFb is hypersecreted by epithelial cells and fibroblasts in the airway as well as the influx of inflammatory cells including eosinophils in asthma (40) . We found significantly less TGFb protein in mice treated with resveratrol than in ovalbumin control mice.
In the current study resveratrol was administered intraperitoneally over a 6 week period. The dose used was efficacious without any side effect in the rodent model as assessed by histopathology of representative (A) (B) (C) Fig. 12 . Immunohistochemical analysis of TGFb1 expression. TGFb1 was investigated by immunohistochemistry in formalinfixed, paraffin-embedded lung tissue sections. Little staining for TGFb1 was observed in the saline-sensitized and -challenged control mice (A). In the lungs of mice receiving chronic OVA sensitization and challenge, staining for TGFb1 was markedly increased (B). Treatment with resveratrol resulted in markedly reduced staining for TGb1 in the lung tissue (C), n010 per group; Bar 0100 mm. organ samples, animal welfare scorings, and bodyweight (data not shown). However, the current study has the caveat that resveratrol was used to prevent disease rather than reverse established disease. Nevertheless, we have provided in vivo evidence for an anti-fibrotic action of resveratrol in inflammatory obstructive lung disease and suppression of AHR in a model of chronic allergic airways disease. Our findings add to the recent literature establishing the anti-fibrotic effects of resveratrol in a wide range of organ systems, providing evidence of key anti-aging properties. Overall, the findings highlight that a dietary and pharmacological approach using resveratrol may represent safe and timely treatment for asthma and lung disease that target a central aspect of airway remodeling and may subvert steroid resistance.
